Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Husain, Mansoor; C. Bain, Stephen; Kleist Jeppesen, Ole; Lingvay, Ildiko; Sørrig, Rasmus; Bach Treppendahl, Marianne; Vilsbøll, Tina

doi:10.1111/dom.13955

Public

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Published in Diabetes Obesity and Metabolism • Jan 6, 2020

Authors:

Mansoor Husain

Stephen C. Bain

Ole Kleist Jeppesen

Abstract

AIM: To investigate the effects of semaglutide versus comparators on major adverse cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) and hospitalization for heart failure (HF) in the SUSTAIN (subcutaneous semaglutide) and PIONEER (oral s...

Subject

Semaglutide

Medicine

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!